View in EDS PDF Full Text

Tolerability and safety of perampanel: two randomized dose-escalation studies.

Saved in:
Bibliographic Details
Title: Tolerability and safety of perampanel: two randomized dose-escalation studies.
Authors: Krauss, G. L., Bar, M., Biton, V., Klapper, J. A., Rektor, I., Vaiciene-Magistris, N., Squillacote, D., Kumar, D.
Source: Acta Neurologica Scandinavica. Jan2012, Vol. 125 Issue 1, p8-15. 8p.
Subjects: Drug tolerance, Medication safety, AMPA receptors, Anticonvulsants, Drug dosage, Randomized controlled trials, Medical statistics
Abstract: Krauss GL, Bar M, Biton V, Klapper JA, Rektor I, Vaiciene-Magistris N, Squillacote D, Kumar D. Tolerability and safety of perampanel: two randomized dose-escalation studies. Acta Neurol Scand: 2012: 125: 8-15. © 2011 John Wiley & Sons A/S. Objectives - To evaluate, for the first time in patients with epilepsy, the tolerability and safety of escalating doses of oral perampanel, a novel, selective, non-competitive AMPA antagonist, as adjunctive therapy for refractory partial-onset seizures. Materials and methods - Two consecutive, randomized, double-blind, dose-escalation studies recruited adults (18-70 years) with uncontrolled partial-onset seizures receiving one to three concomitant antiepileptic drugs. In study 206, patients were treated for 12 weeks (8-week dose-titration, 4-week dose-maintenance) with placebo or perampanel (up to 4 mg/day, dosed once- or twice-daily). In study 208, patients received placebo or perampanel once-daily (up to 12 mg) for 16 weeks (12-week titration, 4-week maintenance). Results - Overall, 153 patients were randomized into study 206 (perampanel twice-daily, n = 51; perampanel once-daily, n = 51; placebo, n = 51). Study 208 included 48 patients (perampanel once-daily, n = 38; placebo, n = 10). The highest dose in study 206 - 4 mg/day - was well tolerated, with similar proportions of patients tolerating once-daily (82.4%) and twice-daily (82.4%) perampanel and placebo (82.4%) treatments. In study 208 most patients tolerated doses of ≥ 6 mg perampanel once-daily in a Kaplan-Meier analysis. In both studies, the most common adverse events were CNS-related; most were of mild/moderate severity. Conclusions - Perampanel was well tolerated across doses of 4-12 mg/day. The studies showed preliminary evidence of efficacy and identified doses to be evaluated in larger clinical studies. [ABSTRACT FROM AUTHOR]
Copyright of Acta Neurologica Scandinavica is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 69870752
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Tolerability and safety of perampanel: two randomized dose-escalation studies.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Krauss%2C+G%2E+L%2E%22">Krauss, G. L.</searchLink><br /><searchLink fieldCode="AR" term="%22Bar%2C+M%2E%22">Bar, M.</searchLink><br /><searchLink fieldCode="AR" term="%22Biton%2C+V%2E%22">Biton, V.</searchLink><br /><searchLink fieldCode="AR" term="%22Klapper%2C+J%2E+A%2E%22">Klapper, J. A.</searchLink><br /><searchLink fieldCode="AR" term="%22Rektor%2C+I%2E%22">Rektor, I.</searchLink><br /><searchLink fieldCode="AR" term="%22Vaiciene-Magistris%2C+N%2E%22">Vaiciene-Magistris, N.</searchLink><br /><searchLink fieldCode="AR" term="%22Squillacote%2C+D%2E%22">Squillacote, D.</searchLink><br /><searchLink fieldCode="AR" term="%22Kumar%2C+D%2E%22">Kumar, D.</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Acta+Neurologica+Scandinavica%22">Acta Neurologica Scandinavica</searchLink>. Jan2012, Vol. 125 Issue 1, p8-15. 8p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Drug+tolerance%22">Drug tolerance</searchLink><br /><searchLink fieldCode="DE" term="%22Medication+safety%22">Medication safety</searchLink><br /><searchLink fieldCode="DE" term="%22AMPA+receptors%22">AMPA receptors</searchLink><br /><searchLink fieldCode="DE" term="%22Anticonvulsants%22">Anticonvulsants</searchLink><br /><searchLink fieldCode="DE" term="%22Drug+dosage%22">Drug dosage</searchLink><br /><searchLink fieldCode="DE" term="%22Randomized+controlled+trials%22">Randomized controlled trials</searchLink><br /><searchLink fieldCode="DE" term="%22Medical+statistics%22">Medical statistics</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Krauss GL, Bar M, Biton V, Klapper JA, Rektor I, Vaiciene-Magistris N, Squillacote D, Kumar D. Tolerability and safety of perampanel: two randomized dose-escalation studies. Acta Neurol Scand: 2012: 125: 8-15. © 2011 John Wiley & Sons A/S. Objectives - To evaluate, for the first time in patients with epilepsy, the tolerability and safety of escalating doses of oral perampanel, a novel, selective, non-competitive AMPA antagonist, as adjunctive therapy for refractory partial-onset seizures. Materials and methods - Two consecutive, randomized, double-blind, dose-escalation studies recruited adults (18-70 years) with uncontrolled partial-onset seizures receiving one to three concomitant antiepileptic drugs. In study 206, patients were treated for 12 weeks (8-week dose-titration, 4-week dose-maintenance) with placebo or perampanel (up to 4 mg/day, dosed once- or twice-daily). In study 208, patients received placebo or perampanel once-daily (up to 12 mg) for 16 weeks (12-week titration, 4-week maintenance). Results - Overall, 153 patients were randomized into study 206 (perampanel twice-daily, n = 51; perampanel once-daily, n = 51; placebo, n = 51). Study 208 included 48 patients (perampanel once-daily, n = 38; placebo, n = 10). The highest dose in study 206 - 4 mg/day - was well tolerated, with similar proportions of patients tolerating once-daily (82.4%) and twice-daily (82.4%) perampanel and placebo (82.4%) treatments. In study 208 most patients tolerated doses of ≥ 6 mg perampanel once-daily in a Kaplan-Meier analysis. In both studies, the most common adverse events were CNS-related; most were of mild/moderate severity. Conclusions - Perampanel was well tolerated across doses of 4-12 mg/day. The studies showed preliminary evidence of efficacy and identified doses to be evaluated in larger clinical studies. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Acta Neurologica Scandinavica is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=69870752
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/j.1600-0404.2011.01588.x
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 8
        StartPage: 8
    Subjects:
      – SubjectFull: Drug tolerance
        Type: general
      – SubjectFull: Medication safety
        Type: general
      – SubjectFull: AMPA receptors
        Type: general
      – SubjectFull: Anticonvulsants
        Type: general
      – SubjectFull: Drug dosage
        Type: general
      – SubjectFull: Randomized controlled trials
        Type: general
      – SubjectFull: Medical statistics
        Type: general
    Titles:
      – TitleFull: Tolerability and safety of perampanel: two randomized dose-escalation studies.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Krauss, G. L.
      – PersonEntity:
          Name:
            NameFull: Bar, M.
      – PersonEntity:
          Name:
            NameFull: Biton, V.
      – PersonEntity:
          Name:
            NameFull: Klapper, J. A.
      – PersonEntity:
          Name:
            NameFull: Rektor, I.
      – PersonEntity:
          Name:
            NameFull: Vaiciene-Magistris, N.
      – PersonEntity:
          Name:
            NameFull: Squillacote, D.
      – PersonEntity:
          Name:
            NameFull: Kumar, D.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Text: Jan2012
              Type: published
              Y: 2012
          Identifiers:
            – Type: issn-print
              Value: 00016314
          Numbering:
            – Type: volume
              Value: 125
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Acta Neurologica Scandinavica
              Type: main
ResultId 1